Pyxis Oncology, Inc., a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, announced the pricing of its upsized initial public offering of 10,500,000 shares of common stock at an initial public offering price of $16.00 per share.
October 7, 2021
· 2 min read